SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

OncoCyte Corp – ‘10-K’ for 12/31/19 – ‘XML’

On:  Wednesday, 3/25/20, at 5:34pm ET   ·   As of:  3/26/20   ·   For:  12/31/19   ·   Accession #:  1493152-20-4738   ·   File #:  1-37648

Previous ‘10-K’:  ‘10-K/A’ on 4/30/19 for 12/31/18   ·   Next:  ‘10-K/A’ on 4/28/20 for 12/31/19   ·   Latest:  ‘10-K’ on 4/16/24 for 12/31/23   ·   6 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/26/20  OncoCyte Corp                     10-K       12/31/19   77:37M                                    M2 Compliance/FA

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML    697K 
 2: EX-4.11     Instrument Defining the Rights of Security Holders  HTML     24K 
 3: EX-10.10    Material Contract                                   HTML     31K 
 4: EX-10.24    Material Contract                                   HTML     32K 
 5: EX-10.34    Material Contract                                   HTML     35K 
 6: EX-10.35    Material Contract                                   HTML     50K 
 7: EX-10.36    Material Contract                                   HTML     97K 
 8: EX-21       Subsidiaries List                                   HTML     22K 
 9: EX-23.1     Consent of Experts or Counsel                       HTML     24K 
10: EX-31       Certification -- §302 - SOA'02                      HTML     37K 
11: EX-32       Certification -- §906 - SOA'02                      HTML     25K 
23: R1          Document and Entity Information                     HTML     61K 
60: R2          Balance Sheets                                      HTML     97K 
67: R3          Balance Sheets (Parenthetical)                      HTML     43K 
49: R4          Statements of Operations                            HTML     63K 
24: R5          Statements of Comprehensive Loss                    HTML     35K 
61: R6          Statements of Shareholders' Equity                  HTML     66K 
68: R7          Statements of Cash Flows                            HTML    133K 
47: R8          Organization, Description of the Business and       HTML     37K 
                Liquidity                                                        
26: R9          Summary of Significant Accounting Policies          HTML     80K 
58: R10         Selected Balance Sheet Components                   HTML     41K 
70: R11         Related Party Transactions                          HTML     40K 
46: R12         Equity Method Investment in Razor Genomics, Inc.    HTML     45K 
25: R13         Loan Payable to Silicon Valley Bank                 HTML     44K 
59: R14         Shareholders' Equity                                HTML     32K 
71: R15         Stock-Based Compensation                            HTML     72K 
48: R16         Income Taxes                                        HTML     50K 
27: R17         Commitments and Contingencies                       HTML     66K 
62: R18         Subsequent Events                                   HTML     35K 
69: R19         Summary of Significant Accounting Policies          HTML    136K 
                (Policies)                                                       
35: R20         Summary of Significant Accounting Policies          HTML     34K 
                (Tables)                                                         
28: R21         Selected Balance Sheet Components (Tables)          HTML     47K 
52: R22         Related Party Transactions (Tables)                 HTML     28K 
74: R23         Equity Method Investment in Razor Genomics, Inc.    HTML     29K 
                (Tables)                                                         
36: R24         Loan Payable to Silicon Valley Bank (Tables)        HTML     29K 
29: R25         Stock-Based Compensation (Tables)                   HTML     70K 
53: R26         Income Taxes (Tables)                               HTML     47K 
75: R27         Commitments and Contingencies (Tables)              HTML     44K 
34: R28         Organization, Description of the Business and       HTML     52K 
                Liquidity (Details Narrative)                                    
30: R29         Summary of Significant Accounting Policies          HTML     81K 
                (Details Narrative)                                              
22: R30         Summary of Significant Accounting Policies -        HTML     33K 
                Schedule of Reconciliation of Cash, Cash                         
                Equivalents, and Restricted Cash (Details)                       
44: R31         Summary of Significant Accounting Policies -        HTML     31K 
                Common Stock Equivalents Excluded from Computation               
                of Diluted Net Loss Per Share of Common Stock                    
                (Details)                                                        
73: R32         Selected Balance Sheet Components (Details          HTML     32K 
                Narrative)                                                       
64: R33         Selected Balance Sheet Components - Schedule of     HTML     34K 
                Prepaid Expenses and Other Current Assets                        
                (Details)                                                        
21: R34         Selected Balance Sheet Components - Schedule of     HTML     31K 
                Deposits and Other Noncurrent Assets (Details)                   
43: R35         Selected Balance Sheet Components - Schedule of     HTML     30K 
                Accrued Expenses and Other Current Liabilities                   
                (Details)                                                        
72: R36         Selected Balance Sheet Components - Schedule of     HTML     36K 
                Right of Use Assets, Machinery and Equipment, Net                
                (Details)                                                        
63: R37         Related Party Transactions (Details Narrative)      HTML     99K 
20: R38         Related Party Transactions - Schedule of Aggregate  HTML     36K 
                Use of Fees Charged (Details)                                    
45: R39         Equity Method Investment in Razor Genomics, Inc.    HTML     80K 
                (Details Narrative)                                              
33: R40         Equity Method Investment in Razor Genomics, Inc. -  HTML     53K 
                Schedule of Condensed Balance Sheet Information                  
                (Details)                                                        
39: R41         Loan Payable to Silicon Valley Bank (Details        HTML    106K 
                Narrative)                                                       
77: R42         Loan Payable to Silicon Valley Bank - Schedule of   HTML     45K 
                Future Cash Payments of Loan Payable (Details)                   
55: R43         Shareholders' Equity (Details Narrative)            HTML     62K 
32: R44         Stock-Based Compensation (Details Narrative)        HTML     76K 
38: R45         Stock-Based Compensation - Summary of Stock Option  HTML     90K 
                Activity (Details)                                               
76: R46         Stock-Based Compensation - Schdule of Stock         HTML     46K 
                Options Outstanding, Vested and Exercisable                      
                (Details)                                                        
54: R47         Stock-Based Compensation - Summary of Stock-based   HTML     31K 
                Compensation Expense (Details)                                   
31: R48         Stock-Based Compensation - Schedule of Assumptions  HTML     35K 
                Used to Calculate Fair Value of Stock Options                    
                (Details)                                                        
40: R49         Income Taxes (Details Narrative)                    HTML     55K 
41: R50         Income Taxes - Schedule of Components of Deferred   HTML     50K 
                Tax Assets and Liabilities (Details)                             
18: R51         Income Taxes - Schedule of Income Tax               HTML     49K 
                Reconciliation (Details)                                         
56: R52         Income Taxes - Schedule of Unrecognized Tax         HTML     31K 
                Benefit (Details)                                                
65: R53         Commitments and Contingencies (Details Narrative)   HTML     67K 
42: R54         Commitments and Contingencies - Schedule of         HTML     31K 
                Supplemental Cash Flow Information Related to                    
                Operating and Financing Lease (Details)                          
19: R55         Commitments and Contingencies - Schedule of         HTML     45K 
                Supplemental Balance Sheet Information Related to                
                Operating and Financing Leases (Details)                         
57: R56         Commitments and Contingencies - Schedule of Future  HTML     70K 
                Minimum Lease Commitments for Operating and                      
                Financing Leases (Details)                                       
66: R57         Subsequent Events (Details Narrative)               HTML     71K 
37: XML         IDEA XML File -- Filing Summary                      XML    131K 
50: EXCEL       IDEA Workbook of Financial Reports                  XLSX     96K 
12: EX-101.INS  XBRL Instance -- ocx-20191231                        XML   1.15M 
14: EX-101.CAL  XBRL Calculations -- ocx-20191231_cal                XML    197K 
15: EX-101.DEF  XBRL Definitions -- ocx-20191231_def                 XML    614K 
16: EX-101.LAB  XBRL Labels -- ocx-20191231_lab                      XML   1.15M 
17: EX-101.PRE  XBRL Presentations -- ocx-20191231_pre               XML    855K 
13: EX-101.SCH  XBRL Schema -- ocx-20191231                          XSD    194K 
51: ZIP         XBRL Zipped Folder -- 0001493152-20-004738-xbrl      Zip    166K

‘XML’   —   IDEA XML File — Filing Summary

This Document is an IDEA XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<FilingSummary>
<Version> 3.20.1 </Version>
<ProcessingTime/>
<ReportFormat> html </ReportFormat>
<ContextCount> 149 </ContextCount>
<ElementCount> 439 </ElementCount>
<EntityCount> 1 </EntityCount>
<FootnotesReported> true </FootnotesReported>
<SegmentCount> 68 </SegmentCount>
<ScenarioCount> 0 </ScenarioCount>
<TuplesReported> false </TuplesReported>
<UnitCount> 5 </UnitCount>
<MyReports>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R1.htm </HtmlFileName>
<LongName> 00000001 - Document - Document and Entity Information </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/DocumentAndEntityInformation </Role>
<ShortName> Document and Entity Information </ShortName>
<MenuCategory> Cover </MenuCategory>
<Position> 1 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R2.htm </HtmlFileName>
<LongName> 00000002 - Statement - Balance Sheets </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/BalanceSheets </Role>
<ShortName> Balance Sheets </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 2 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R3.htm </HtmlFileName>
<LongName> 00000003 - Statement - Balance Sheets (Parenthetical) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/BalanceSheetsParenthetical </Role>
<ShortName> Balance Sheets (Parenthetical) </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 3 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R4.htm </HtmlFileName>
<LongName> 00000004 - Statement - Statements of Operations </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/StatementsOfOperations </Role>
<ShortName> Statements of Operations </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 4 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R5.htm </HtmlFileName>
<LongName> 00000005 - Statement - Statements of Comprehensive Loss </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/StatementsOfComprehensiveLoss </Role>
<ShortName> Statements of Comprehensive Loss </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 5 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R6.htm </HtmlFileName>
<LongName> 00000006 - Statement - Statements of Shareholders' Equity </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/StatementsOfShareholdersEquity </Role>
<ShortName> Statements of Shareholders' Equity </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 6 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R7.htm </HtmlFileName>
<LongName> 00000007 - Statement - Statements of Cash Flows </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/StatementsOfCashFlows </Role>
<ShortName> Statements of Cash Flows </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 7 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R8.htm </HtmlFileName>
<LongName> 00000008 - Disclosure - Organization, Description of the Business and Liquidity </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidity </Role>
<ShortName> Organization, Description of the Business and Liquidity </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 8 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R9.htm </HtmlFileName>
<LongName> 00000009 - Disclosure - Summary of Significant Accounting Policies </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/SummaryOfSignificantAccountingPolicies </Role>
<ShortName> Summary of Significant Accounting Policies </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 9 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R10.htm </HtmlFileName>
<LongName> 00000010 - Disclosure - Selected Balance Sheet Components </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/SelectedBalanceSheetComponents </Role>
<ShortName> Selected Balance Sheet Components </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 10 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R11.htm </HtmlFileName>
<LongName> 00000011 - Disclosure - Related Party Transactions </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/RelatedPartyTransactions </Role>
<ShortName> Related Party Transactions </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 11 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R12.htm </HtmlFileName>
<LongName> 00000012 - Disclosure - Equity Method Investment in Razor Genomics, Inc. </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/EquityMethodInvestmentInRazorGenomicsInc. </Role>
<ShortName> Equity Method Investment in Razor Genomics, Inc. </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 12 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R13.htm </HtmlFileName>
<LongName> 00000013 - Disclosure - Loan Payable to Silicon Valley Bank </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/LoanPayableToSiliconValleyBank </Role>
<ShortName> Loan Payable to Silicon Valley Bank </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 13 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R14.htm </HtmlFileName>
<LongName> 00000014 - Disclosure - Shareholders' Equity </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/ShareholdersEquity </Role>
<ShortName> Shareholders' Equity </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 14 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R15.htm </HtmlFileName>
<LongName> 00000015 - Disclosure - Stock-Based Compensation </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/Stock-basedCompensation </Role>
<ShortName> Stock-Based Compensation </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 15 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R16.htm </HtmlFileName>
<LongName> 00000016 - Disclosure - Income Taxes </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/IncomeTaxes </Role>
<ShortName> Income Taxes </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 16 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R17.htm </HtmlFileName>
<LongName> 00000017 - Disclosure - Commitments and Contingencies </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/CommitmentsAndContingencies </Role>
<ShortName> Commitments and Contingencies </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 17 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R18.htm </HtmlFileName>
<LongName> 00000018 - Disclosure - Subsequent Events </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/SubsequentEvents </Role>
<ShortName> Subsequent Events </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 18 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R19.htm </HtmlFileName>
<LongName> 00000019 - Disclosure - Summary of Significant Accounting Policies (Policies) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies </Role>
<ShortName> Summary of Significant Accounting Policies (Policies) </ShortName>
<MenuCategory> Policies </MenuCategory>
<ParentRole> http://oncocyte.com/role/SummaryOfSignificantAccountingPolicies </ParentRole>
<Position> 19 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R20.htm </HtmlFileName>
<LongName> 00000020 - Disclosure - Summary of Significant Accounting Policies (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesTables </Role>
<ShortName> Summary of Significant Accounting Policies (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://oncocyte.com/role/SummaryOfSignificantAccountingPolicies </ParentRole>
<Position> 20 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R21.htm </HtmlFileName>
<LongName> 00000021 - Disclosure - Selected Balance Sheet Components (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/SelectedBalanceSheetComponentsTables </Role>
<ShortName> Selected Balance Sheet Components (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://oncocyte.com/role/SelectedBalanceSheetComponents </ParentRole>
<Position> 21 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R22.htm </HtmlFileName>
<LongName> 00000022 - Disclosure - Related Party Transactions (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/RelatedPartyTransactionsTables </Role>
<ShortName> Related Party Transactions (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://oncocyte.com/role/RelatedPartyTransactions </ParentRole>
<Position> 22 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R23.htm </HtmlFileName>
<LongName> 00000023 - Disclosure - Equity Method Investment in Razor Genomics, Inc. (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/EquityMethodInvestmentInRazorGenomicsInc.Tables </Role>
<ShortName> Equity Method Investment in Razor Genomics, Inc. (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://oncocyte.com/role/EquityMethodInvestmentInRazorGenomicsInc. </ParentRole>
<Position> 23 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R24.htm </HtmlFileName>
<LongName> 00000024 - Disclosure - Loan Payable to Silicon Valley Bank (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/LoanPayableToSiliconValleyBankTables </Role>
<ShortName> Loan Payable to Silicon Valley Bank (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://oncocyte.com/role/LoanPayableToSiliconValleyBank </ParentRole>
<Position> 24 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R25.htm </HtmlFileName>
<LongName> 00000025 - Disclosure - Stock-Based Compensation (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/Stock-basedCompensationTables </Role>
<ShortName> Stock-Based Compensation (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://oncocyte.com/role/Stock-basedCompensation </ParentRole>
<Position> 25 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R26.htm </HtmlFileName>
<LongName> 00000026 - Disclosure - Income Taxes (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/IncomeTaxesTables </Role>
<ShortName> Income Taxes (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://oncocyte.com/role/IncomeTaxes </ParentRole>
<Position> 26 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R27.htm </HtmlFileName>
<LongName> 00000027 - Disclosure - Commitments and Contingencies (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/CommitmentsAndContingenciesTables </Role>
<ShortName> Commitments and Contingencies (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://oncocyte.com/role/CommitmentsAndContingencies </ParentRole>
<Position> 27 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R28.htm </HtmlFileName>
<LongName> 00000028 - Disclosure - Organization, Description of the Business and Liquidity (Details Narrative) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative </Role>
<ShortName> Organization, Description of the Business and Liquidity (Details Narrative) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidity </ParentRole>
<Position> 28 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R29.htm </HtmlFileName>
<LongName> 00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative </Role>
<ShortName> Summary of Significant Accounting Policies (Details Narrative) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesTables </ParentRole>
<Position> 29 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R30.htm </HtmlFileName>
<LongName> 00000030 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails </Role>
<ShortName> Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 30 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R31.htm </HtmlFileName>
<LongName> 00000031 - Disclosure - Summary of Significant Accounting Policies - Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share of Common Stock (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/SummaryOfSignificantAccountingPolicies-CommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareOfCommonStockDetails </Role>
<ShortName> Summary of Significant Accounting Policies - Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share of Common Stock (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 31 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R32.htm </HtmlFileName>
<LongName> 00000032 - Disclosure - Selected Balance Sheet Components (Details Narrative) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/SelectedBalanceSheetComponentsDetailsNarrative </Role>
<ShortName> Selected Balance Sheet Components (Details Narrative) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://oncocyte.com/role/SelectedBalanceSheetComponentsTables </ParentRole>
<Position> 32 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R33.htm </HtmlFileName>
<LongName> 00000033 - Disclosure - Selected Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/SelectedBalanceSheetComponents-ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails </Role>
<ShortName> Selected Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 33 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R34.htm </HtmlFileName>
<LongName> 00000034 - Disclosure - Selected Balance Sheet Components - Schedule of Deposits and Other Noncurrent Assets (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/SelectedBalanceSheetComponents-ScheduleOfDepositsAndOtherNoncurrentAssetsDetails </Role>
<ShortName> Selected Balance Sheet Components - Schedule of Deposits and Other Noncurrent Assets (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 34 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R35.htm </HtmlFileName>
<LongName> 00000035 - Disclosure - Selected Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/SelectedBalanceSheetComponents-ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails </Role>
<ShortName> Selected Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 35 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R36.htm </HtmlFileName>
<LongName> 00000036 - Disclosure - Selected Balance Sheet Components - Schedule of Right of Use Assets, Machinery and Equipment, Net (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/SelectedBalanceSheetComponents-ScheduleOfRightOfUseAssetsMachineryAndEquipmentNetDetails </Role>
<ShortName> Selected Balance Sheet Components - Schedule of Right of Use Assets, Machinery and Equipment, Net (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 36 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R37.htm </HtmlFileName>
<LongName> 00000037 - Disclosure - Related Party Transactions (Details Narrative) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative </Role>
<ShortName> Related Party Transactions (Details Narrative) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://oncocyte.com/role/RelatedPartyTransactionsTables </ParentRole>
<Position> 37 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R38.htm </HtmlFileName>
<LongName> 00000038 - Disclosure - Related Party Transactions - Schedule of Aggregate Use of Fees Charged (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/RelatedPartyTransactions-ScheduleOfAggregateUseOfFeesChargedDetails </Role>
<ShortName> Related Party Transactions - Schedule of Aggregate Use of Fees Charged (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 38 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R39.htm </HtmlFileName>
<LongName> 00000039 - Disclosure - Equity Method Investment in Razor Genomics, Inc. (Details Narrative) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/EquityMethodInvestmentInRazorGenomicsInc.DetailsNarrative </Role>
<ShortName> Equity Method Investment in Razor Genomics, Inc. (Details Narrative) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://oncocyte.com/role/EquityMethodInvestmentInRazorGenomicsInc.Tables </ParentRole>
<Position> 39 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R40.htm </HtmlFileName>
<LongName> 00000040 - Disclosure - Equity Method Investment in Razor Genomics, Inc. - Schedule of Condensed Balance Sheet Information (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/EquityMethodInvestmentInRazorGenomicsInc.-ScheduleOfCondensedBalanceSheetInformationDetails </Role>
<ShortName> Equity Method Investment in Razor Genomics, Inc. - Schedule of Condensed Balance Sheet Information (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 40 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R41.htm </HtmlFileName>
<LongName> 00000041 - Disclosure - Loan Payable to Silicon Valley Bank (Details Narrative) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative </Role>
<ShortName> Loan Payable to Silicon Valley Bank (Details Narrative) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://oncocyte.com/role/LoanPayableToSiliconValleyBankTables </ParentRole>
<Position> 41 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R42.htm </HtmlFileName>
<LongName> 00000042 - Disclosure - Loan Payable to Silicon Valley Bank - Schedule of Future Cash Payments of Loan Payable (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/LoanPayableToSiliconValleyBank-ScheduleOfFutureCashPaymentsOfLoanPayableDetails </Role>
<ShortName> Loan Payable to Silicon Valley Bank - Schedule of Future Cash Payments of Loan Payable (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 42 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R43.htm </HtmlFileName>
<LongName> 00000043 - Disclosure - Shareholders' Equity (Details Narrative) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/ShareholdersEquityDetailsNarrative </Role>
<ShortName> Shareholders' Equity (Details Narrative) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://oncocyte.com/role/ShareholdersEquity </ParentRole>
<Position> 43 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R44.htm </HtmlFileName>
<LongName> 00000044 - Disclosure - Stock-Based Compensation (Details Narrative) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative </Role>
<ShortName> Stock-Based Compensation (Details Narrative) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://oncocyte.com/role/Stock-basedCompensationTables </ParentRole>
<Position> 44 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R45.htm </HtmlFileName>
<LongName> 00000045 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/Stock-basedCompensation-SummaryOfStockOptionActivityDetails </Role>
<ShortName> Stock-Based Compensation - Summary of Stock Option Activity (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 45 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R46.htm </HtmlFileName>
<LongName> 00000046 - Disclosure - Stock-Based Compensation - Schdule of Stock Options Outstanding, Vested and Exercisable (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/Stock-basedCompensation-SchduleOfStockOptionsOutstandingVestedAndExercisableDetails </Role>
<ShortName> Stock-Based Compensation - Schdule of Stock Options Outstanding, Vested and Exercisable (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 46 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R47.htm </HtmlFileName>
<LongName> 00000047 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/Stock-basedCompensation-SummaryOfStock-basedCompensationExpenseDetails </Role>
<ShortName> Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 47 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R48.htm </HtmlFileName>
<LongName> 00000048 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used to Calculate Fair Value of Stock Options (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/Stock-basedCompensation-ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails </Role>
<ShortName> Stock-Based Compensation - Schedule of Assumptions Used to Calculate Fair Value of Stock Options (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 48 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R49.htm </HtmlFileName>
<LongName> 00000049 - Disclosure - Income Taxes (Details Narrative) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/IncomeTaxesDetailsNarrative </Role>
<ShortName> Income Taxes (Details Narrative) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://oncocyte.com/role/IncomeTaxesTables </ParentRole>
<Position> 49 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R50.htm </HtmlFileName>
<LongName> 00000050 - Disclosure - Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/IncomeTaxes-ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails </Role>
<ShortName> Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 50 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R51.htm </HtmlFileName>
<LongName> 00000051 - Disclosure - Income Taxes - Schedule of Income Tax Reconciliation (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/IncomeTaxes-ScheduleOfIncomeTaxReconciliationDetails </Role>
<ShortName> Income Taxes - Schedule of Income Tax Reconciliation (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 51 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R52.htm </HtmlFileName>
<LongName> 00000052 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefit (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/IncomeTaxes-ScheduleOfUnrecognizedTaxBenefitDetails </Role>
<ShortName> Income Taxes - Schedule of Unrecognized Tax Benefit (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 52 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R53.htm </HtmlFileName>
<LongName> 00000053 - Disclosure - Commitments and Contingencies (Details Narrative) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative </Role>
<ShortName> Commitments and Contingencies (Details Narrative) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://oncocyte.com/role/CommitmentsAndContingenciesTables </ParentRole>
<Position> 53 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R54.htm </HtmlFileName>
<LongName> 00000054 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/CommitmentsAndContingencies-ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeaseDetails </Role>
<ShortName> Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 54 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R55.htm </HtmlFileName>
<LongName> 00000055 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/CommitmentsAndContingencies-ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails </Role>
<ShortName> Commitments and Contingencies - Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 55 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R56.htm </HtmlFileName>
<LongName> 00000056 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Commitments for Operating and Financing Leases (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails </Role>
<ShortName> Commitments and Contingencies - Schedule of Future Minimum Lease Commitments for Operating and Financing Leases (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 56 </Position>
</Report>
<Report instance="ocx-20191231.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R57.htm </HtmlFileName>
<LongName> 00000057 - Disclosure - Subsequent Events (Details Narrative) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://oncocyte.com/role/SubsequentEventsDetailsNarrative </Role>
<ShortName> Subsequent Events (Details Narrative) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://oncocyte.com/role/SubsequentEvents </ParentRole>
<Position> 57 </Position>
</Report>
<Report>
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<LongName> All Reports </LongName>
<ReportType> Book </ReportType>
<ShortName> All Reports </ShortName>
</Report>
</MyReports>
<InputFiles>
<File> ocx-20191231.xml </File>
<File> ocx-20191231.xsd </File>
<File> ocx-20191231_cal.xml </File>
<File> ocx-20191231_def.xml </File>
<File> ocx-20191231_lab.xml </File>
<File> ocx-20191231_pre.xml </File>
</InputFiles>
<SupplementalFiles/>
<BaseTaxonomies>
<BaseTaxonomy> http://fasb.org/srt/2019-01-31 </BaseTaxonomy>
<BaseTaxonomy> http://xbrl.sec.gov/dei/2019-01-31 </BaseTaxonomy>
<BaseTaxonomy> http://fasb.org/us-gaap/2019-01-31 </BaseTaxonomy>
</BaseTaxonomies>
<HasPresentationLinkbase> true </HasPresentationLinkbase>
<HasCalculationLinkbase> true </HasCalculationLinkbase>
</FilingSummary>

6 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/16/24  Oncocyte Corp.                    10-K       12/31/23   87:30M                                    M2 Compliance LLC/FA
 4/12/23  Oncocyte Corp.                    10-K       12/31/22   94:11M                                    M2 Compliance LLC/FA
 5/02/22  Oncocyte Corp.                    10-K/A     12/31/21   12:649K                                   M2 Compliance LLC/FA
 3/11/22  Oncocyte Corp.                    10-K       12/31/21   90:10M                                    M2 Compliance LLC/FA
 4/30/21  OncoCyte Corp.                    10-K/A     12/31/20    2:488K                                   M2 Compliance LLC/FA
 3/19/21  OncoCyte Corp.                    10-K       12/31/20   93:7.4M                                   M2 Compliance LLC/FA
↑Top
Filing Submission 0001493152-20-004738   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Mon., Apr. 29, 2:19:20.1pm ET